GaPP2 clinical trial
GaPP2 is a multi-centre, double blind randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women.
WHY?: To test the hypothesis that treatment with gabapentin has the potential to provide an effective oral treatment to alleviate pain and improve quality of life in women with chronic pelvic pain in the absence of any obvious pelvic pathology.
WHO?: Women aged between 18-50 years, who are suffering from non-cyclical chronic pelvic pain (>3 months). “Negative” laparoscopy >2 weeks but <36 months ago and are using/willing to use effective contraception if necessary.
WHERE?: 36 sites across the UK
RECRUITMENT TARGET: 300 women
The GaPP2 trial was published in The Lancet in September 2020:
Research Article: Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. doi: 10.1016/S0140-6736(20)31693-7